BVF Partners
44 Montgomery StreetSan Francisco, CA 94104
Website: bvflp.com
Firm Size
- Assets Under Management (AUM):$6.1 Billion
- Number of Funds:4
- Employees:15
- Firm Type:Hedge Fund
Description
BVF Partners L.P. is a San Francisco-based hedge fund investment firm that specializes in the healthcare sector. The firm was founded in 1993 by Mark Lampert and focuses on providing long-term capital appreciation through a concentrated portfolio of publicly traded biotechnology and pharmaceutical companies. BVF Partners L.P. operates with a fundamental research-based approach, combining rigorous analysis and industry expertise to identify attractive investment opportunities within the healthcare industry. The firm actively manages its portfolio, seeking to generate value by actively engaging with companies and their management teams to drive positive change and growth. The investment strategy of BVF Partners L.P. is centered around investing in small to mid-cap companies with promising drug pipelines or innovative technologies that have the potential to address unmet medical needs. The firm often takes significant stakes in these companies and works closely with their management to support their strategic objectives. With a successful track record spanning several decades, BVF Partners L.P. has established itself as a reputable and influential player in the healthcare investment landscape. The firm's expertise and experience in the biotechnology and pharmaceutical industries make it a sought-after partner for both investors and the companies it invests in. Overall, BVF Partners L.P. is a prominent hedge fund investment firm specializing in the healthcare sector, leveraging its industry knowledge and active engagement approach to generate long-term value for its investors.Latest News
Powered by
May 21, 2024: Pheon Therapeutics announces $120m Series B financing to fund development of its differentiated ADC pipeline
Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces the completion of a $120m Series B financing to fund the development of its pipeline of differentiated ADCs. The financing was led by TCGX with participation from other new investors BVF Partners, Lightspeed and Perceptive Advisors, alongside existing investors Atlas Venture, Brandon Capital, Forbion, and Research Corporation Technologies.
Feb 02, 2024: Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the PIPE) for gross proceeds of approximately $200 million .
Nov 08, 2023: Forward Therapeutics Announces $50 Million Series A Financing to Advance Next-Generation Small Molecule Immune Therapies
Forward Therapeutics, Inc., a biopharmaceutical company developing next-generation small molecule therapies for chronic immunological and inflammatory disorders, today announced a $50 million Series A financing. The financing was led by BVF Partners LP with participation from other leading life sciences investors RA Capital Management and OrbiMed.